

Jill Bargonetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8469973/publications.pdf>

Version: 2024-02-01

56
papers

5,784
citations

201385

27
h-index

174990

52
g-index

57
all docs

57
docs citations

57
times ranked

6656
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. <i>Molecular Pharmaceutics</i> , 2021, 18, 338-346.	2.3	6
2	Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. <i>Oncotarget</i> , 2021, 12, 1128-1146.	0.8	4
3	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. <i>Molecular Pharmaceutics</i> , 2021, 18, 3418-3428.	2.3	16
4	Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772315.	1.8	3
5	Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 394-405.	0.4	48
6	<p>MDM2-C Functions as an E3 Ubiquitin Ligase</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7715-7724.	0.9	4
7	A Protein in the Yeast <i>Saccharomyces cerevisiae</i> Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. <i>Biomolecules</i> , 2020, 10, 417.	1.8	2
8	Gain-of-function mutant p53: history and speculation. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 605-609.	1.5	59
9	MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 257-269.	1.1	9
10	Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. <i>Breast Cancer Research</i> , 2019, 21, 5.	2.2	30
11	Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. <i>Oncotarget</i> , 2019, 10, 5007-5010.	0.8	2
12	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, .	2.3	50
13	Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. <i>Oncotarget</i> , 2017, 8, 47916-47930.	0.8	23
14	Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 22.	1.2	17
15	Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. <i>Cell Cycle</i> , 2015, 14, 744-754.	1.3	9
16	Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate <i>VEGFR2</i> in breast cancer cells. <i>Genes and Development</i> , 2015, 29, 1298-1315.	2.7	115
17	Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1220-9.	3.3	72
18	Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. <i>Oncotarget</i> , 2015, 6, 34573-34591.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Splice Variants of MDM2 in Oncogenesis. <i>Sub-Cellular Biochemistry</i> , 2014, 85, 247-261.	1.0	15
20	<i>C. elegans</i> CEP-1/p53 and BEC-1 Are Involved in DNA Repair. <i>PLoS ONE</i> , 2014, 9, e88828.	1.1	18
21	Impedimetric Detection of Mutant p53 Biomarker-Driven Metastatic Breast Cancers under Hypotonic Pressure. <i>PLoS ONE</i> , 2014, 9, e99351.	1.1	7
22	Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator. <i>PLoS ONE</i> , 2013, 8, e77643.	1.1	23
23	Splicing Up Mdm2 for Cancer Proteome Diversity. <i>Genes and Cancer</i> , 2012, 3, 311-319.	0.6	28
24	8-Amino-Adenosine Activates p53-Independent Cell Death of Metastatic Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2495-2504.	1.9	8
25	Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. <i>Cell</i> , 2012, 148, 244-258.	13.5	736
26	Dietary downregulation of mutant p53 levels via glucose restriction. <i>Cell Cycle</i> , 2012, 11, 4436-4446.	1.3	111
27	A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. <i>Breast Cancer Research</i> , 2011, 13, R3.	2.2	71
28	Differential Toxicity of DNA Adducts of Mitomycin C. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-6.	0.8	41
29	DNA Adducts of Decarbamoyl Mitomycin C Efficiently Kill Cells without Wild-Type p53 Resulting from Proteasome-Mediated Degradation of Checkpoint Protein 1. <i>Chemical Research in Toxicology</i> , 2010, 23, 1151-1162.	1.7	19
30	Mapping DNA Adducts of Mitomycin C and Decarbamoyl Mitomycin C in Cell Lines Using Liquid Chromatography/Electrospray Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2008, 21, 2370-2378.	1.7	32
31	Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. <i>Ethnicity and Disease</i> , 2008, 18, S2-1-8.	1.0	11
32	Mitomycinâ€“DNA Adducts Induce p53-Dependent and p53-Independent Cell Death Pathways. <i>ACS Chemical Biology</i> , 2007, 2, 399-407.	1.6	34
33	Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. <i>Oncogene</i> , 2006, 25, 7305-7310.	2.6	176
34	Mouse Double Minute 2 Associates with Chromatin in the Presence of p53 and Is Released to Facilitate Activation of Transcription. <i>Cancer Research</i> , 2006, 66, 3463-3470.	0.4	32
35	A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 26776-26787.	1.6	106
36	The p53 Network. , 2005, , 1-23.		2

#	ARTICLE	IF	CITATIONS
37	Phospholipase D Elevates the Level of MDM2 and Suppresses DNA Damage-Induced Increases in p53. <i>Molecular and Cellular Biology</i> , 2004, 24, 5677-5686.	1.1	64
38	Inhibition of Human p53 Basal Transcription by Down-regulation of Protein Kinase C β . <i>Journal of Biological Chemistry</i> , 2004, 279, 9970-9977.	1.6	57
39	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. <i>Cell</i> , 2004, 119, 591-602.	13.5	1,158
40	In Vivo Footprinting and DNA Affinity Chromatography for Analysis of p53 DNA Binding Ability. , 2003, 234, 151-170.		2
41	Differential Activation of p53 by the Various Adducts of Mitomycin C. <i>Journal of Biological Chemistry</i> , 2002, 277, 40513-40519.	1.6	50
42	Multiple roles of the tumor suppressor p53. <i>Current Opinion in Oncology</i> , 2002, 14, 86-91.	1.1	301
43	Camptothecin and Zeocin Can Increase p53 Levels during All Cell Cycle Stages. <i>Biochemical and Biophysical Research Communications</i> , 2001, 289, 998-1009.	1.0	17
44	Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 383-390.	1.0	55
45	Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. , 1999, 5, 219-227.		148
46	p53 binds to a constitutively nucleosome free region of the mdm2 gene. <i>Oncogene</i> , 1998, 16, 1171-1181.	2.6	28
47	DNA-binding Properties of the p53 Tumor Suppressor Protein. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1994, 59, 207-213.	2.0	16
48	The p53 protein is an unusually shaped tetramer that binds directly to DNA.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3319-3323.	3.3	242
49	Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.. <i>Genes and Development</i> , 1992, 6, 1886-1898.	2.7	220
50	Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.. <i>Genes and Development</i> , 1992, 6, 1143-1152.	2.7	317
51	Wild-type p53 activates transcription in vitro. <i>Nature</i> , 1992, 358, 83-86.	13.7	615
52	Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. <i>Cell</i> , 1991, 65, 1083-1091.	13.5	404
53	Functional Consequences of the Interactions of the p53 Tumor Suppressor Protein and SV40 Large Tumor Antigen. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1991, 56, 227-235.	2.0	14
54	Initiation of rolling-circle replication in pT181 plasmid: initiator protein enhances cruciform extrusion at the origin.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 8560-8564.	3.3	106

#	ARTICLE	IF	CITATIONS
55	Staphylococcus aureus chromosomal mutations that decrease efficiency of Rep utilization in replication of pT181 and related plasmids. Journal of Bacteriology, 1989, 171, 4501-4503.	1.0	24
56	How Choreostorming Informs Thinking In Molecular Genetics And Cancer Biology. Leonardo, 0, , 1-8.	0.2	1